http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Quadruple Primary Malignancies of Liver, Bladder, Lung and Stomach in One Patient
Yhim, Ho-Young,Kim, Hee Sun,Lee, Na-Ri,Kwak, Jae-Yong,Yim, Chang-Yeol,Park, Ho Sung,Song, Eun-Kee SAGE Publications 2010 TUMORI Vol.96 No.5
<P>Multiple primary malignancies are defined as two or more malignancies in an individual without any relationship between the tumors. Because of advances in the early detection, treatment, and supportive care for cancer, the number of cancer survivors has been gradually increasing, and this has led to an increase in the possible occurrence of subsequent malignancies. Recently, there have been reports that smoking is associated with a specific genetic mutation (the tumor suppressor gene TP53), and this genetic predisposition may be related to the development of multiple primary malignancies. Here we present a rare case of quadruple primary malignancies of the liver, bladder, lung and stomach, some of which possibly linked to smoking-related TP53 mutation. Because of its extreme rarity and the clear relationship between multiple primary malignancies and smoking-related TP53 mutation, we report this case along with a review of the relevant literature.</P>
Yhim, Ho-Young,Han, Sae-Won,Oh, Do-Youn,Han, Wonshik,Im, Seock-Ah,Kim, Tae-You,Kim, Young Tae,Noh, Dong-Young,Chie, Eui Kyu,Ha, Sung Whan,Park, In Ae,Bang, Yung-Jue Wiley Subscription Services, Inc., A Wiley Company 2010 Cancer Vol.116 No.12
<B>BACKGROUND:</B><P>The aim of this study was to evaluate the clinical treatment outcomes of recurrent breast cancer with a limited number of isolated lung metastases, and to evaluate the role of pulmonary metastasectomy.</P><B>METHODS:</B><P>The authors consecutively enrolled 140 recurrent breast cancer patients with isolated lung metastasis from 1997 to 2007 in Seoul National University Hospital and retrospectively analyzed 45 patients who had <4 metastatic lesions.</P><B>RESULTS:</B><P>Fifteen patients had pulmonary metastasectomy followed by systemic treatment (pulmonary metastasectomy group), and 30 received systemic treatment alone (nonpulmonary metastasectomy group). The 3-year progression-free survival (PFS) and 4-year overall survival (OS) was significantly longer in the pulmonary metastasectomy group than in the nonpulmonary metastasectomy group (3-year PFS, 55.0% vs 4.5%, P < .001; 4-year OS, 82.1% vs 31.6%, P = .001). In multivariate analysis, a disease-free interval (DFI) of <24 months (hazard ratio [HR], 4.53; 95% CI, 1.72-11.90), no pulmonary metastasectomy (HR, 9.52; 95% CI, 3.34-27.18) and biologic subtypes such as human epithelial growth factor receptor-2 positive (HR, 3.00; 95% CI, 1.04-8.64) and triple negative (HR, 3.92; 95% CI, 1.32-11.59) were independent prognostic factors for shorter PFS.</P><B>CONCLUSIONS:</B><P>The authors' results demonstrated that DFI and biologic subtypes of tumor are firm, independent, prognostic factors for survival, and pulmonary metastasectomy can be a reasonable treatment option in this population. Further prospective studies are warranted to evaluate the role of pulmonary metastasectomy. Cancer 2010. © 2010 American Cancer Society.</P>
Yhim, H-Y,Kim, K,Kim, J S,Kang, H J,Kim, J-A,Min, C-K,Bae, S H,Park, E,Yang, D-H,Suh, C,Kim, M K,Mun, Y-C,Eom, H S,Shin, H J,Yoon, H-J,Kwon, J H,Lee, J H,Kim, Y S,Yoon, S-S,Kwak, J-Y Macmillan Publishers Limited 2013 Bone marrow transplantation Vol.48 No.3
The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.
YHIM, HO-YOUNG,CHO, SANG-HEE,KIM, SAM YONG,CHO, IN SUNG,LEE, KYU TAEK,LEE, WON SUP,LEE, SOON IL,PARK, MOO RIM,PARK, SANG-GON,HAN, HYE-SUK,CHOI, YOON SEOK,CHUNG, IK-JOO,SHIM, HYUN-JEONG,LEE, NA-RI,SONG Spandidos Publications 2015 ONCOLOGY REPORTS Vol.34 No.1
<P>Thymidylate synthase (TS) gene polymorphisms such as tandem repeat (TR) polymorphisms and single-nucleotide polymorphisms (SNPs) affect transcriptional efficiency of the TS gene and may be prognostic markers for fluoropyrimidine-based therapy in various gastrointestinal cancers. However, data for TS polymorphisms on clinical outcomes in advanced small bowel adenocarcinoma (SBA) are limited. We retrospectively enrolled 58 locally advanced/metastatic SBA patients treated with first-line fluoropyrimidine-based chemotherapy and analyzed the relationship between TS genotypes and clinical outcomes in 30 patients who were available for tumor tissue. Based on TR polymorphisms and a G>C SNP in the promoter region of the TS gene, 74% of patients had high TS expression genotypes (2R/3RG, 3RG/3RC, 3RG/3RG); the remainder had low TS expression genotypes (2R/2R, 2R/3RC, 3RC/3RC). After a median follow-up of 48.8 months, median progression-free survival (PFS) and overall survival (OS) in all patients were 6.0 and 11.3 months, respectively. However, patients with low TS expression genotypes had better median PFS (12.8 vs. 4.3 months, P=0.027) and OS (28.8 vs. 8.9 months, P=0.025) than those with high TS expression genotypes. In multivariate analysis, poor Eastern Cooperative Oncology Group performance status [hazard ratio (HR), 2.85; 95% CI, 1.02-7.93] and high TS expression genotypes (HR, 3.49; 95% CI, 1.13-10.78) were independent prognostic factors for worse OS. Therefore, TS genotypes, based on a G>C SNP in the TR sequence of the TS gene, may be a useful biomarker for predicting outcomes for fluoropyrimidine-based chemotherapy in patients with locally advanced/metastatic SBA.</P>
임학빈(Yhim Hark P),김성기(Kim Sung Ki),이지영(Lee Ji Young) 충남대학교 회계연구소 2005 회계논집 Vol.6 No.2
90년대 중반 이후 회계정보에 의한 기업가치 평가는 가장 활발히 연구되어온 자본시장회계연구이다. 다수의 연구들은 미래현금흐름의 대용치인 전통적인 재무제표변수가 얼마나 기업가치를 평가할 수 있는가하는 가치관련성(value relevance)에 집중되어 있다. 본 연구는 우리나라 자본시장에서 회계정보의 기업가치 관련성 변화를 실증분석하였다. 본 연구의 실증분석 결과는 미국 자본시장을 대상으로 한 Francis and Schipper(1999)의 연구결과와 동일하다. 보다 직접적인 비교를 위하여 1980-1990년대의 표본과 2000-2003년대의 표본의 회계이익 및 장부가치 기울기계수의 차이검증을 위한 회귀모형에서도 통계적으로 유의한 차이를 나타냈다.